Human Metabolome Technologies, Inc. (TYO:6090)

Market Cap	4.07B
Revenue (ttm)	1.40B
Net Income (ttm)	265.00M
Shares Out	5.89M
EPS (ttm)	44.79
PE Ratio	15.45
Forward PE	n/a
Dividend	15.00 (2.17%)
Ex-Dividend Date	Jun 27, 2025

Volume	8,800
Average Volume	6,260
Open	692.00
Previous Close	692.00
Day's Range	676.00 - 701.00
52-Week Range	501.00 - 723.00
Beta	0.22
RSI	54.50
Earnings Date	May 14, 2025

About TYO:6090

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, prec...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2003
• Employees: 58
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6090

Financial Performance

In 2024, TYO:6090's revenue was 1.35 billion, an increase of 3.54% compared to the previous year's 1.30 billion. Earnings were 243.00 million, a decrease of -14.74%.